• Je něco špatně v tomto záznamu ?

Antihypertensive mechanisms of chronic captopril or N-acetylcysteine treatment in L-NAME hypertensive rats

Josef Zicha, Zdenka Dobešová, Jaroslav Kuneš

. 2006 ; 29 (12) : 1021-1027.

Jazyk angličtina Země Japonsko

Typ dokumentu práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc13028316

Grantová podpora
NR7786 MZ0 CEP - Centrální evidence projektů

Hypertension due to chronic inhibition of NO synthase (NOS) by Nomega-nitro-L-arginine methyl ester (L-NAME) administration is characterized by both impaired NO-dependent vasodilation and enhanced sympathetic vasoconstriction. The aim of our study was to evaluate changes in the participation of major vasoactive systems in L-NAME-treated rats which were subjected to simultaneous antihypertensive (captopril) or antioxidant (N-acetylcysteine, NAC) treatment. Three-month-old Wistar males treated with L-NAME (60 mg/kg/day) for 5 weeks were compared to rats in which L-NAME treatment was combined with simultaneous chronic administration of captopril or NAC. Basal blood pressure (BP) and its acute responses to consecutive i.v. injections of captopril (10 mg/kg), pentolinium (5 mg/kg), L-NAME (30 mg/kg), tetraethylammonium (TEA, 16 mg/kg) and nitroprusside (NP, 20 microg/kg) were determined in conscious rats at the end of the study. The development of L-NAME hypertension was prevented by captopril treatment, whereas NAC treatment caused only a moderate BP reduction. Captopril treatment normalized the sympathetic BP component and significantly reduced residual BP (measured at full NP-induced vasodilation). In contrast, chronic NAC treatment did not modify the sympathetic BP component or residual BP, but significantly enhanced NO-dependent vasodilation. Neither captopril nor NAC treatment influenced the compensatory increase of TEA-sensitive vasodilation mediated by endothelium-derived hyperpolarizing factor in L-NAME-treated rats. Chronic captopril treatment prevented L-NAME hypertension by lowering of sympathetic tone, whereas chronic NAC treatment attenuated L-NAME hypertension by reduction in the vasodilator deficit due to enhanced NO-dependent vasodilation.

Citace poskytuje Crossref.org

Bibliografie atd.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc13028316
003      
CZ-PrNML
005      
20130905091113.0
007      
ta
008      
130902s2006 ja d f 000 0|eng||
009      
AR
024    7_
$a 10.1291/hypres.29.1021 $2 doi
035    __
$a (PubMed)17378375
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ja
100    1_
$a Zicha, Josef, $d 1950- $7 jk01152609 $u Institute of Physiology AS CR and Cardiovascular Research Center, Prague, Czech Republic
245    10
$a Antihypertensive mechanisms of chronic captopril or N-acetylcysteine treatment in L-NAME hypertensive rats / $c Josef Zicha, Zdenka Dobešová, Jaroslav Kuneš
504    __
$a Literatura
520    9_
$a Hypertension due to chronic inhibition of NO synthase (NOS) by Nomega-nitro-L-arginine methyl ester (L-NAME) administration is characterized by both impaired NO-dependent vasodilation and enhanced sympathetic vasoconstriction. The aim of our study was to evaluate changes in the participation of major vasoactive systems in L-NAME-treated rats which were subjected to simultaneous antihypertensive (captopril) or antioxidant (N-acetylcysteine, NAC) treatment. Three-month-old Wistar males treated with L-NAME (60 mg/kg/day) for 5 weeks were compared to rats in which L-NAME treatment was combined with simultaneous chronic administration of captopril or NAC. Basal blood pressure (BP) and its acute responses to consecutive i.v. injections of captopril (10 mg/kg), pentolinium (5 mg/kg), L-NAME (30 mg/kg), tetraethylammonium (TEA, 16 mg/kg) and nitroprusside (NP, 20 microg/kg) were determined in conscious rats at the end of the study. The development of L-NAME hypertension was prevented by captopril treatment, whereas NAC treatment caused only a moderate BP reduction. Captopril treatment normalized the sympathetic BP component and significantly reduced residual BP (measured at full NP-induced vasodilation). In contrast, chronic NAC treatment did not modify the sympathetic BP component or residual BP, but significantly enhanced NO-dependent vasodilation. Neither captopril nor NAC treatment influenced the compensatory increase of TEA-sensitive vasodilation mediated by endothelium-derived hyperpolarizing factor in L-NAME-treated rats. Chronic captopril treatment prevented L-NAME hypertension by lowering of sympathetic tone, whereas chronic NAC treatment attenuated L-NAME hypertension by reduction in the vasodilator deficit due to enhanced NO-dependent vasodilation.
590    __
$a bohemika - dle Pubmed
650    02
$a acetylcystein $x farmakologie $x terapeutické užití $7 D000111
650    02
$a zvířata $7 D000818
650    02
$a antihypertenziva $x farmakologie $x terapeutické užití $7 D000959
650    02
$a krevní tlak $x účinky léků $7 D001794
650    02
$a kaptopril $x farmakologie $x terapeutické užití $7 D002216
650    02
$a hypertenze $x chemicky indukované $x prevence a kontrola $7 D006973
650    02
$a mužské pohlaví $7 D008297
650    02
$a NG-nitroargininmethylester $x antagonisté a inhibitory $x farmakologie $7 D019331
650    02
$a nitroprusid $x farmakologie $x terapeutické užití $7 D009599
650    02
$a pentoliniumtartrát $x farmakologie $x terapeutické užití $7 D010425
650    02
$a krysa rodu Rattus $7 D051381
650    02
$a potkani Wistar $7 D017208
650    02
$a Tetraethylammonium $x pd [Pharmacology]
650    02
$a Tetraethylammonium $x tu [Therapeutic Use]
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Dobešová, Zdena, $d 1947- $7 xx0074152 $u Institute of Physiology AS CR and Cardiovascular Research Center, Prague, Czech Republic
700    1_
$a Kuneš, Jaroslav, $d 1948- $7 nlk19990073450 $u Institute of Physiology AS CR and Cardiovascular Research Center, Prague, Czech Republic
773    0_
$t Hypertension Research - Clinical & Experimental $x 0916-9636 $g Roč. 29, č. 12 (2006), s. 1021-1027 $p Hypertens Res $w MED00006041
773    0_
$p Hypertens Res $g 29(12):1021-7, 2006 Dec $x 0916-9636
910    __
$a ABA008 $y 3 $z 0
990    __
$a 20130902140339 $b ABA008
991    __
$a 20130905091602 $b ABA008
999    __
$a ok $b bmc $g 992294 $s 826748
BAS    __
$a 3
BMC    __
$x MED00006041 $i 0916-9636 $a 2006 $b 29 $c 12 $d 1021-1027 $m Hypertension research
GRA    __
$a NR7786 $p MZ0
LZP    __
$a 2013-09/gvbo

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...